Braveheart Bio reported earnings of -$ 0.51 per BRVE share on Nov 10, 2026, beating analysts' expectations by
| Report Date | Nov 10, 2026 |
|---|---|
| Forecasted EPS | -$ 0.44 |
| Earnings Per Share (Surprise) | -$ 0.51 (-$ 0.07) |
Out of the last 2 earnings reporting periods, Braveheart Bio beat analysts’ expectations 0 times and fell short of expectations 2 time(s). Braveheart Bio reported earnings per share of -$ 0.51 in the last report falling to reach an estimated EPS of -$ 0.44 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.44 | -$ 0.51 | - | - |
| Sep 8, 2026 | $ 2.69 | -$ 2.51 | - | - |
Braveheart Bio’s stock was trading at $ 19.46 on Nov 9, 2026 a day before the last earnings report was released.Following the release of the earnings report, BRVE’s price increased to $ 20.90 on Nov 11, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.51 | $ 19.46 | $ 20.90 | |
| Sep 8, 2026 | -$ 2.51 | $ 26.74 | $ 28.91 |
Braveheart Bio released its most recent earnings reports in November 2026, September 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Braveheart Bio missed analysts’ expectations during the last earnings period by
